<DOC>
	<DOCNO>NCT00549965</DOCNO>
	<brief_summary>Compare subject satisfaction week dose 35 mg Risedronate daily dose 5 mg Risedronate postmenopausal osteoporotic woman . Secondary objective measure compliance ( 50 % drug take ) , persistence .</brief_summary>
	<brief_title>Satisfaction Compliance Risedronate PMO</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<criteria>Five ( 5 ) year great postmenopausal present diagnosis postmenopausal osteoporosis base standard clinical practice criterion . Subjects must discontinue bisphosphonates , calcitonin , fluoride , glucocorticoid ( &gt; = 5 mg prednisone equivalent per day ) hormone replacement therapy include estrogenrelated compound least 6 month prior randomization . During study , drug permit study medication , Risedronate . Other concomitant medication keep minimum , drug consider necessary subject 's welfare unlikely interfere study medication may give discretion Investigator . Had history cancer within past 5 year . Relatively benign skin malignancy , basal cell carcinoma squamous cell carcinoma , exclusion subject remission least 6 month prior enrollment . Diagnosis hypocalcemia , hyperparathyroidism , hyperthyroidism . History alcohol and/or drug abuse . Subjects exclude active gastrointestinal disease may interfere absorption ability swallow oral medication . Subjects also exclude serious concurrent illness would interfere ability participate trial . Excluded medication : bisphosphonates , calcitonin fluoride hormone replacement therapy within last 6 month . Known hypersensitivity bisphosphonates and/or excipients . Abnormal laboratory parameter , clinically relevant accord Investigator ( include renal insufficiency ; creatinine clearance &lt; 30 mL/min ) The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>